## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence presented in the abstract; no access to full text, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The authors report that Axitinib, a second-generation tyrosine kinase inhibitor used for metastatic renal cell carcinoma, binds to DNA with a binding constant of (5.13 +/- 0.28) x 10(4) determined by electrochemical methods. They propose a groove-binding mode, supported by molecular docking and molecular dynamics simulations, in which the drug binds to the DNA minor groove via partial intercalation, forms new hydrogen bonds, and separates guanine and cytosine base pairs.
- **Visible evidence base** Abstract text only; no experimental data, spectra, simulation parameters, or statistical analyses are visible
- **Missing materials affecting confidence** Full methods, all figures and tables, simulation setup and trajectory analyses, error analysis details, and any control experiments

## Reviewer
- **Overall assessment** The abstract presents a plausible and potentially interesting study on drug-DNA interactions, but the evidence base available for review is limited to the abstract. The central claim of minor groove binding with partial intercalation is supported only by a single binding constant and qualitative statements about docking and simulation outcomes. The mechanistic conclusion, particularly the separation of guanine and cytosine base pairs, is not quantitatively substantiated in the provided material. The study may be of interest to researchers in drug-DNA interaction and anticancer pharmacology, but the current evidence is insufficient to fully establish the proposed binding mode.
- **Who would be interested in the results, and why** Researchers in nucleic acid chemistry, biophysical chemistry, and anticancer drug development would be interested in the binding mode of Axitinib to DNA, as it may inform structure-activity relationships for tyrosine kinase inhibitors with DNA-targeting properties. Computational chemists working on docking and molecular dynamics of ligand-DNA systems may also find the in-silico approach relevant.
- **Major strengths** The study combines multiple experimental techniques with computational methods, which is a commendable integrative approach. The use of electrochemical methods to derive a binding constant provides a quantitative anchor for the interaction. The explicit proposal of a specific binding mode, minor groove with partial intercalation, offers a testable hypothesis.
- **Major Concerns** 
  - R1-M1
  - R1-M2
  - R1-M3
- **Minor Comments** 
  - R1-m1
  - R1-m2
  - R1-m3
- **Technical failings that need to be addressed before the case is established** The binding constant alone does not distinguish groove binding from intercalation; additional evidence such as viscosity measurements, ionic strength dependence, or competitive displacement assays would be needed. The claim of base pair separation from molecular dynamics is not supported by any quantitative metric in the abstract, such as root-mean-square deviation or hydrogen bond occupancy. The consistency between experimental and computational results is asserted but not demonstrated with comparative data.
- **Assessment against Nature-style criteria** Originality: moderate, as drug-DNA interaction studies are common, but the specific focus on Axitinib is novel. Scientific importance: limited at this stage, as the clinical relevance of DNA binding for Axitinib efficacy is not established. Interdisciplinary readership: the topic bridges pharmacology and biophysics, but the abstract does not clearly articulate broader implications. Technical soundness: cannot be fully assessed from the abstract; the methods are named but not detailed. Readability for nonspecialists: the abstract is accessible but uses technical terms without sufficient context for a general audience.
- **Recommendation posture** Currently not established from the provided evidence. The abstract suggests a potentially valid study, but the core mechanistic claims require full experimental and computational data to be verified.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence sufficiency
- **Claim pointer** The binding constant of (5.13 +/- 0.28) x 10(4) suggests groove binding.
- **Evidence pointer** Electrochemical studies, location not provided
- **Concern** The abstract states that the binding constant value indicates groove binding, but a single binding constant value is not diagnostic of a specific binding mode. Intercalators and groove binders can exhibit overlapping ranges of binding constants depending on ionic strength, temperature, and DNA sequence.
- **Why it matters** The central mechanistic conclusion of the study depends on correctly assigning the binding mode. Without corroborating evidence, the claim is underdetermined.
- **Resolution test** Provide additional experimental data, such as viscosity measurements, DNA melting temperature shifts under varied conditions, or competitive binding assays with known groove binders and intercalators, to confirm the binding mode.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Computational validation
- **Claim pointer** Molecular docking and molecular dynamics simulations indicate selective minor groove binding with partial intercalation and separation of guanine and cytosine base pairs.
- **Evidence pointer** In-silico analyses, location not provided
- **Concern** The abstract reports qualitative outcomes from docking and simulations but provides no quantitative metrics, such as binding free energies, root-mean-square deviation values, or hydrogen bond occupancy over simulation time. The claim of base pair separation is particularly strong and requires quantitative support.
- **Why it matters** Without quantitative simulation data, the computational results cannot be independently evaluated, and the claim of base pair separation may be an artifact of simulation conditions or insufficient sampling.
- **Resolution test** Report key simulation parameters, convergence criteria, and quantitative measures of DNA structural changes, such as base pair distance over time, to substantiate the claim.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** No
- **Axis** Integration of experimental and computational results
- **Claim pointer** The electrochemical finding is further supported by in-silico analyses.
- **Evidence pointer** Electrochemical studies and in-silico analyses, location not provided
- **Concern** The abstract asserts that computational results support the experimental finding, but no direct comparison is shown. For example, the computed binding affinity is not compared to the experimental binding constant, and the proposed binding mode is not cross-validated with experimental probes.
- **Why it matters** The strength of a multi-method study lies in the convergence of independent lines of evidence. Without explicit integration, the support is only rhetorical.
- **Resolution test** Provide a direct comparison of experimental and computational binding affinities or a discussion of how simulation results align with experimental observables, such as melting temperature changes or spectral shifts.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity
- **Affected element** Introduction of the clinical rationale
- **Evidence pointer** Abstract, first sentence
- **Issue** The abstract states that Axitinib has a strong affinity for DNA, which leads to disruption of the double helix, but this is presented as a fact without citation or context. The clinical relevance of DNA binding for a tyrosine kinase inhibitor is not self-evident.
- **Required correction** Clarify whether the DNA binding is a known mechanism of action or a hypothesis, and provide context for why this interaction is relevant to the drug's therapeutic effect.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Terminology
- **Affected element** Use of "partial intercalation"
- **Evidence pointer** Abstract, in-silico analyses
- **Issue** The term "partial intercalation" is not standard and may be ambiguous. It is unclear whether this refers to a specific structural mode or a transient state.
- **Required correction** Define the term or use established terminology, such as "minor groove binding with partial insertion of a functional group," to avoid confusion.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Completeness
- **Affected element** Experimental techniques listed
- **Evidence pointer** Abstract, methods list
- **Issue** The abstract lists UV-Vis spectroscopy, thermal denaturation assays, electrochemical methods, and fluorescence emission spectroscopy, but only electrochemical results are reported. The outcomes of the other techniques are not mentioned.
- **Required correction** Briefly state the key findings from each technique or explain why they are omitted from the abstract.

## Risk / unsupported claims
- The claim that Axitinib disrupts the double helix structure and halts the cell cycle is presented as a mechanism of action but is not supported by data in the abstract.
- The assertion that the binding constant suggests groove binding is underdetermined without additional experimental evidence.
- The claim of base pair separation from molecular dynamics is unsupported by quantitative data in the abstract.
- The statement that computational results support experimental findings is not demonstrated with comparative data.